» Articles » PMID: 27611696

Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress

Abstract

Thermal ablative therapies are important treatment options in the multidisciplinary care of patients with hepatocellular carcinoma (HCC), but lesions larger than 2-3 cm are plagued with high local recurrence rates and overall survival of these patients remains poor. Currently no adjuvant therapies exist to prevent local HCC recurrence in patients undergoing thermal ablation. The molecular mechanisms mediating HCC resistance to thermal ablation induced heat stress and local recurrence remain unclear. Here we demonstrate that the HCC cells with a poor prognostic hepatic stem cell subtype (Subtype HS) are more resistant to heat stress than HCC cells with a better prognostic hepatocyte subtype (Subtype HC). Moreover, sublethal heat stress rapidly induces phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dependent-protein kinase B (AKT) survival signaling in HCC cells in vitro and at the tumor ablation margin in vivo. Conversely, inhibition of PI3K/mTOR complex 2 (mTORC2)-dependent AKT phosphorylation or direct inhibition of AKT function both enhance HCC cell killing and decrease HCC cell survival to sublethal heat stress in both poor and better prognostic HCC subtypes while mTOR complex 1 (mTORC1)-inhibition has no impact. Finally, we showed that AKT isoforms 1, 2 and 3 are differentially upregulated in primary human HCCs and that overexpression of AKT correlates with worse tumor biology and pathologic features (AKT3) and prognosis (AKT1). Together these findings define a novel molecular mechanism whereby heat stress induces PI3K/mTORC2-dependent AKT survival signaling in HCC cells and provide a mechanistic rationale for adjuvant AKT inhibition in combination with thermal ablation as a strategy to enhance HCC cell killing and prevent local recurrence, particularly at the ablation margin.

Citing Articles

Fibroblast growth factors induce hepatic tumorigenesis post radiofrequency ablation.

Markezana A, Paldor M, Liao H, Ahmed M, Zorde-Khvalevsky E, Rozenblum N Sci Rep. 2023; 13(1):16341.

PMID: 37770545 PMC: 10539492. DOI: 10.1038/s41598-023-42819-2.


Recent Perspectives on the Mechanism of Recurrence After Ablation of Hepatocellular Carcinoma: A Mini-Review.

Yang J, Guo W, Lu M Front Oncol. 2022; 12:895678.

PMID: 36081558 PMC: 9445307. DOI: 10.3389/fonc.2022.895678.


Severe heat stress modulated nuclear factor erythroid 2-related factor 2 and macrophage migration inhibitory factor pathway in rat liver.

Gupta A, Sharma D, Gupta H, Singh A, Chowdhury D, Ganju L J Cell Commun Signal. 2022; 16(4):547-566.

PMID: 35260968 PMC: 9733776. DOI: 10.1007/s12079-022-00668-0.


Quantitative Expression of Key Cancer Markers in the AS-30D Hepatocarcinoma Model.

Briones-Orta M, Delgado-Coello B, Gutierrez-Vidal R, Sosa-Garrocho M, Macias-Silva M, Mas-Oliva J Front Oncol. 2021; 11:670292.

PMID: 34737944 PMC: 8561839. DOI: 10.3389/fonc.2021.670292.


Moderate hyperthermic heating encountered during thermal ablation increases tumor cell activity.

Markezana A, Ahmed M, Kumar G, Zorde-Khvalevsky E, Rozenblum N, Galun E Int J Hyperthermia. 2020; 37(1):119-129.

PMID: 31969029 PMC: 7654730. DOI: 10.1080/02656736.2020.1714084.


References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

2.
Bruix J, Gores G, Mazzaferro V . Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5):844-55. PMC: 4337888. DOI: 10.1136/gutjnl-2013-306627. View

3.
Cho Y, Kim J, Kim M, Rhim H, Han J . Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2008; 49(2):453-9. DOI: 10.1002/hep.22648. View

4.
Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S . Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 2004; 103(2):307-12. DOI: 10.1002/cncr.20774. View

5.
Rush J, Moritz A, Lee K, Guo A, Goss V, Spek E . Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2004; 23(1):94-101. DOI: 10.1038/nbt1046. View